Top Markets
Coin of the day
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
주식 순위 #39465
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
주가
$0.11725176
마지막 동기화: 2025-07-14
시가총액
$481.50K
변동 (1일)
-0.20%
변동 (1년)
0.00%
국가
FR
거래 PHAXIAM Therapeutics S.A. (PHXM)

카테고리

PHAXIAM Therapeutics S.A. (PHXM)의 EPS
June 2024 기준 EPS TTM: $-4.23
PHAXIAM Therapeutics S.A.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-4.23입니다. 2022년 말에는 회사의 EPS가 $-0.07였으며, 이는 2021년의 EPS $-23.87와 감소입니다.
PHAXIAM Therapeutics S.A.의 EPS 기록 (2016 ~ 2026)
매년 말의 EPS
연도 EPS 변화
2026 (TTM) $-4.23 -23.50%
2023 $-5.53 7,492.45%
2022 $-0.07 -99.69%
2021 $-23.87 -46.82%
2020 $-44.88 23.87%
2019 $-36.23 60.03%
2018 $-22.64 -30.76%
2017 $-32.70 21.96%
2016 $-26.81 0.00%
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
$17.32 -509.44%
US
$27.74 -755.76%
NL
- -
CH
- -
KR
$13.70 -423.86%
BE